Efficacy of preconditioning should be gauged by reduction of infarction

British Journal of Pharmacology

Volumn 141, Issue 2, 2004, Pages 197-198

  Cohen, Michael V ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; BRADYKININ; CLAMIKALANT; CYCLIC GMP DEPENDENT PROTEIN KINASE; MINOXIDIL; MITOGEN ACTIVATED PROTEIN KINASE; OPIATE; PROTEIN KINASE C; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; SYNAPTOPHYSIN;

ALOPECIA; CELL SURFACE; CONDITIONING; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; MITOCHONDRION; NOTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REDUCTION; REVASCULARIZATION; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION;

EID: 1342301484     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705612     Document Type: Note

References (13)

1. BIRINCIOGLU, M., YANG, X.-M., CRITZ, S.D., COHEN, M.V. & DOWNEY, J.M. (1999). S-T segment voltage during sequential coronary occlusions is an unreliable marker of preconditioning. Am. J. Physiol., 277, H2435-H2441.
2. BOLLI, R. & MARBÁN, E. (1999). Molecular and cellular mechanisms of myocardial stunning. Physiol. Rev., 79, 609-634.
3. COHEN, M.V. & DOWNEY, J.M. (2001). Ischemic preconditioning: description, mechanism, and significance. In: Heart Physiology and Pathophysiology, 4th edn., ed. Sperelakis, N., Kurachi, Y., Terzic, A. & Cohen, M.V. pp. 867-885. San Diego: Academic Press.
4. GELPI, R.J., MORALES, C., COHEN, M.V. & DOWNEY, J.M. (2002). Xanthine oxidase contributes to preconditioning's preservation of left ventricular developed pressure in isolated rat heart: developed pressure may not be an appropriate end-point for studies of preconditioning. Basic Res. Cardiol., 97, 40-46.
5. ATP channels in cardioprotection. Basic Res. Cardiol., 95, 280-284.
6. JENKINS, D.P., PUGSLEY, W.B. & YELLON, D.M. (1995). Ischaemic preconditioning in a model of global ischaemia: infarct size limitation, but no reduction of stunning. J. Mol. Cell. Cardiol., 27, 1623-1632.
7. KRIEG, T., QIN, Q., MCINTOSH, E.C., COHEN, M.V. & DOWNEY, J.M. (2002). ACh and adenosine activate PI3-kinase in rabbit hearts through transactivation of receptor tyrosine kinases. Am. J. Physiol., 283, H2322-H2330.
8. LOCHNER, A., GENADE, S. & MOOLMAN, J.A. (2003). Ischemic preconditioning: infarct size is a more reliable endpoint than functional recovery. Basic Res. Cardiol., 98, 337-346.
9. MAROKO, P.R., KJEKSHUS, J.K., SOBEL, B.E., WATANABE, T., COVELL, J.W., ROSS JR, J. & BRAUNWALD, E. (1971). Factors influencing infarct size following experimental coronary artery occlusions. Circulation, 43, 67-82.
10. MURRY, C.E., JENNINGS, R.B. & REIMER, K.A. (1986). Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 74, 1124-1136.
11. ATP channel opening and leads to cardioprotection. Am. J. Physiol., (in press).
12. ATP channels and confers cardioprotection. Br. J. Pharmacol., 141, 360-366.
13. TONG, H., CHEN, W., STEENBERGEN, C. & MURPHY, E. (2000). Ischemic preconditioning activates phosphatidylinositol-3-kinase upstream of protein kinase C. Circ. Res., 87, 309-315.